Showing results (571-580 of 700) with videos related to
Sort By:
Pageof 70
Breast Cancer Research and Treatment|September 27, 2012
Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriersKristen N Stevens, Xianshu Wang, Zachary Fredericksen, et al.Nature|September 9, 2010
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaGideon Bollag, Peter Hirth, James Tsai, et al.Nature Genetics|April 23, 2002
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutationsHanne Meijers-Heijboer, Ans van den Ouweland, Jan Klijn, et al.NPJ Breast Cancer|June 27, 2017
A functionally significant SNP in TP53 and breast cancer risk in African-American womenMaureen E Murphy, Song Liu, Song Yao, et al.European Journal of Human Genetics : EJHG|August 24, 2018
Correction: Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriersLogan C Walker, Louise Marquart, John F Pearson, et al.Biorxiv : the Preprint Server for Biology|September 10, 2024
Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancerAnton Safonov, Antonio Marra, Chaitanya Bandlamudi, et al.DNA and Cell Biology|February 25, 2012
Isolation and preliminary characterization of amino acid substitution mutations that increase the activity of the osmoregulated ProP protein of Salmonella enterica serovar TyphimuriumBrittany J Gasper, Jennifer C McCreight, Katelyn Banschbach, et al.NPJ Breast Cancer|September 23, 2020
Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancerTaru A Muranen, Sofia Khan, Rainer Fagerholm, et al.Cancer Research|July 18, 2020
A Rare TP53 Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple CancersJacquelyn Powers, Emilia M Pinto, Thibaut Barnoud, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2023
Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2Siddhartha Yadav, Nicholas J Boddicker, Jie Na, et al.Pageof 70